DOCSLIB.ORG

Quantitative Phosphoproteomics Unravels Biased Phosphorylation Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantitative Phosphoproteomics Unravels Biased Phosphorylation Of Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser 280 by Hallucinogenic versus Nonhallucinogenic Agonists Samah Karaki, Carine Becamel, Samy Murat, Clotilde Mannoury La Cour, Mark Millan, Laurent Prézeau, Joël Bockaert, Philippe Marin, Franck Vandermoere To cite this version: Samah Karaki, Carine Becamel, Samy Murat, Clotilde Mannoury La Cour, Mark Millan, et al.. Quan- titative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser 280 by Hallucinogenic versus Nonhallucinogenic Agonists. Molecular and Cellular Proteomics, American Soci- ety for Biochemistry and Molecular Biology, 2014, 13 (5), pp.1273-1285. 10.1074/mcp.M113.036558. hal-02366017 HAL Id: hal-02366017 https://hal.archives-ouvertes.fr/hal-02366017 Submitted on 15 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Research © 2014 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists*□S Samah Karaki‡§¶ʈ, Carine Becamel‡§¶ʈ, Samy Murat‡‡¶ʈ, Clotilde Mannoury la Cour**, Mark J. Millan**, Laurent Pre´ zeau‡§¶ʈ, Joe¨ l Bockaert‡§¶ʈ, Philippe Marin‡§¶ʈ§§, and Franck Vandermoere‡§¶ʈ‡‡§§ The serotonin 5-HT2A receptor is a primary target of psy- induced a less pronounced desensitization of receptor- chedelic hallucinogens such as lysergic acid diethyl- operated signaling in HEK-293 cells and neurons than did amine, mescaline, and psilocybin, which reproduce some nonhallucinogenic agonists. The mutation of Ser280 to as- of the core symptoms of schizophrenia. An incompletely partic acid (to mimic phosphorylation) reduced receptor resolved paradox is that only some 5-HT2A receptor ago- desensitization by nonhallucinogenic agonists, whereas nists exhibit hallucinogenic activity, whereas structurally its mutation to alanine increased the ability of hallucino- related agonists with comparable affinity and activity lack gens to desensitize the receptor. This study reveals a such a psychoactive activity. Using a strategy combining biased phosphorylation of the 5-HT2A receptor in re- stable isotope labeling by amino acids in cell culture with sponse to hallucinogenic versus nonhallucinogenic ago- enrichment in phosphorylated peptides by means of hy- nists, which underlies their distinct capacity to desensi- drophilic interaction liquid chromatography followed by tize the receptor. Molecular & Cellular Proteomics 13: immobilized metal affinity chromatography, we compared 10.1074/mcp.M113.036558, 1273–1285, 2014. the phosphoproteome in HEK-293 cells transiently express- ing the 5-HT2A receptor and exposed to either vehicle or the synthetic hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2- Among the G Protein-Coupled Receptors (GPCRs)1 acti- aminopropane (DOI) or the nonhallucinogenic 5-HT2A ago- nist lisuride. Among the 5995 identified phosphorylated vated by serotonin (5-hydroxytryptamine, 5-HT), the 5-HT2A peptides, 16 sites were differentially phosphorylated upon receptor continues to attract particular attention in view of its exposure of cells to DOI versus lisuride. These include a broad physiological role and implication in the actions of serine (Ser280) located in the third intracellular loop of the numerous psychotropic agents (1, 2). It is a primary target of 5-HT2A receptor, a region important for its desensitiza- widely used atypical antipsychotics such as clozapine, risperi- tion. The specific phosphorylation of Ser280 by hallucino- done, and olanzapine, which act as antagonists or inverse gens was further validated by quantitative mass spec- agonists (1, 3). The activation of 5-HT2A receptors expressed trometry analysis of immunopurified receptor digests and in the prefrontal cortex has also been implicated in the psy- by Western blotting using a phosphosite specific anti- cho-mimetic effects of psychedelic hallucinogens, such as body. The administration of DOI, but not of lisuride, to lysergic acid diethylamide (LSD), mescaline, and psilocybin, mice, enhanced the phosphorylation of 5-HT receptors 2A which are often used to model positive symptoms of schizo- at Ser280 in the prefrontal cortex. Moreover, hallucinogens phrenia (4–8). However, these psychoactive effects are not reproduced by structurally-related agonists, such as ergota- From the ‡CNRS, UMR-5203, Institut de Ge´ nomique Fonctionnelle, mine and the anti-Parkinson agent lisuride, despite the fact F-34094 Montpellier, France; §INSERM, U661, F-34094 Montpellier, that they exhibit comparable affinities and efficacies at 5-HT2A France; ¶Universite´ Montpellier 1, F-34094 Montpellier, France; ʈUni- receptors (7, 9). This paradox was partially resolved by the versite´ Montpellier 2, F-34094 Montpellier, France; **Institut de Re- demonstration that hallucinogens induce a specific transcrip- cherches Servier, Croissy-sur-Seine, France Received November 27, 2013, and in revised form, February 19, 2014 1 The abbreviations used are: GPCR, G protein-coupled receptor; Published, MCP Papers in Press, March 17, 2014, DOI 10.1074/ 5-HT, 5-hydroxytryptamine, serotonin; DOI, 1-[2,5-dimethoxy-4-iodo- mcp.M113.036558 phenyl]-2-aminopropane; HILIC, hydrophilic interaction liquid chro- Author contributions: C.M., M.J.M., J.B., P.M., and F.V. designed matography; LSD, lysergic acid diethylamine; PKB, Protein Kinase B; research; S.K., S.M., P.M., and F.V. performed research; C.B. and PKC, Protein Kinase C; PLC, phospholipase C; PTX, Pertussis toxin; L.P. contributed new reagents or analytic tools; S.K. and F.V. ana- RSK, Ribosomal S6 kinase; SILAC, stable isotope labeling by amino lyzed data; M.J.M., J.B., P.M., and F.V. wrote the paper. acids in cell culture. Molecular & Cellular Proteomics 13.5 1273 Biased 5-HT2A Receptor Phosphorylation tomic signature because of the specific engagement of a and arginine, supplemented with 10% dialyzed serum and either 2 Pertussis toxin-sensitive G /Src signaling pathway which is L-lysine/L-arginine for light label (K0R0, L) or L-Lysine-2HCl ( H4, i/o 13 96–98%)/L-Arginine-HCl ( C6, 99%) for semi-heavy label (K4R6, M) not activated by nonhallucinogenic agonists (7, 8). These 13 15 13 or L-Lysine-2HCl ( C6, 99%; N2, 99%)/L-Arginine-HCl ( C6, 99%; findings suggest that hallucinogenic and nonhallucinogenic 15 N4, 99%) for heavy label (K8R10, H) (percentages represent the agonists induce different conformational states of the 5-HT2A isotopic purity of the labeled amino acids). Under these conditions, receptor, and represent a striking example of functional se- analysis of semi-heavy amino acid incorporation at the protein level lectivity that translates into contrasting pattern of mice behav- indicated a median ratio of 93% (first quartile at 88%, third quartile at ior: induction of head-twitches by hallucinogenic but not by 95%). A similar distribution was observed for the incorporation of the heavy amino acids. nonhallucinogenic agonists (9). Primary cultures of cortical neurons were prepared as described The differential influence of hallucinogenic versus nonhallu- previously (14). Briefly, dissociated cells from the cerebral cortex of 17 cinogenic agonists on signaling pathways suggests that they day-old Swiss mouse embryos were plated on 6- or 96-well plates trigger contrasting patterns of protein phosphorylation. To coated successively with poly-l-ornithine (mol. Wt. ϭ 40,000; 15 ␮ ϩ ␮ address this issue, we employed a quantitative phosphopro- g/ml) and 10% fetal calf serum 1 g/ml laminin. The culture medium included a 1:1 mixture of DMEM and F-12 nutrient supple- teomics strategy to directly compare the phosphoproteomes mented with 33 mM glucose, 2 mM glutamine, 13 mM NaHCO3,5mM generated in HEK-293 cells by the synthetic hallucinogen HEPES buffer, pH 7.4, 5 IU/ml (5 mg/ml) penicillin-streptomycin, and 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) and a mixture of salt and hormones containing 100 ␮g/ml transferin, 25 ␮ the nonhallucinogenic 5-HT2A agonist lisuride. We found that g/ml insulin, 20 nM progesterone, 60 nM putrescine, and 30 nM DOI, but not lisuride, induced the phosphorylation of a serine Na2SeO3. Cultures were infected 5 days after seeding with the Sind- bis virus expressing HA-tagged 5-HT receptor and were used 7 residue (Ser280) located in the third intracellular loop of the 2A days after seeding. At this stage, they were shown to contain at least receptor itself. The hallucinogen-specific phosphorylation of 95% of neurons (14). this residue was further validated in vitro and in vivo by using Global Quantitative Phosphoproteomics Analyses—HEK-293 cells a phosphosite-specific antibody. These findings were fol- grown in SILAC media and transiently expressing 5-HT2A receptors lowed by a series of experiments to determine the impact of were serum-starved for 4 h and challenged for 15 min with either ␮ ␮ Ser280 phosphorylation upon receptor desensitization and vehicle (L), or lisuride
Load more

Recommended publications
  • Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid
    Clinical Policy: Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description • When using a preferred agent where applicable, the number of tablets/doses allowed per month will be restricted based on the manufacturer’s package insert and/or Buckeye Health plans quantity limits. CNS AGENTS: ANTI-MIGRAINE AGENTS – ACUTE MIGRANE TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” “PREFERRED” NARATRIPTAN (GENERIC OF AMERGE®) NURTEC™ ODT (rimegepant) ALMOTRIPTAN (generic of Axert®) RIZATRIPTAN TABLETS (GENERIC OF CAFERGOT® (ergotamine w/caffeine) MAXALT®) ELETRIPTAN (generic of Relpax®) RIZATRIPTAN ODT (GENERIC OF ERGOMAR® (ergotamine) MAXALT-MLT®) FROVA® (frovatriptan) SUMATRIPTAN TABLETS, NASAL SPRAY, MIGERGOT® (ergotamine w/caffeine) INJECTION (GENERIC OF MIGRANAL® (dihydroergotamine) IMITREX®) ONZETRA™ XSAIL™ (sumatriptan) REYVOW™ (lasmiditan) SUMAVEL DOSEPRO® (sumatriptan) TOSYMRA® (sumatriptan) TREXIMET® (sumatriptan/naproxen) UBRELVY™ (ubrogepant)* ZOLMITRIPTAN (generic of Zomig®) ZOLMITRIPTAN ODT (generic of Zomig ZMT®) ZOMIG® NASAL SPRAY (zolmitriptan) CNS AGENTS: ANTI-MIGRAINE AGENTS – CLUSTER HEADACHE TREATMENT NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” VERAPAMIL (Generic of Calan®) EMGALITY™ (galcanezumab) VERAPAMIL SR/ER (Generic of Calan SR®, Isoptin SR®, Verelan®) CNS AGENTS: ANTI-MIGRAINE AGENTS – PROPHYLAXIS TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” (Trials of at least 3 controller “PREFERRED” medications) Cardiovascular Agents: Beta-blockers AIMOVIG™ (erenumab-aooe) † EMGALITY™ (galcanezumab) CNS Agents: Anticonvulsants AJOVY™ (fremanezumab-vfrm) * CNS Agents: Serotonin-norepinephrine reuptake inhibitors CNS Agents: Tricyclic antidepressants †Initial Dose is limited to 70mg once monthly; may request dose increase if 70mg fails to provide adequate relief over two consecutive months.
    [Show full text]
  • Biased Ligands Differentially Shape the Conformation of The
    International Journal of Molecular Sciences Article Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors Katrin Denzinger, Trung Ngoc Nguyen, Theresa Noonan, Gerhard Wolber and Marcel Bermudez * Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany; [email protected] (K.D.); [email protected] (T.N.N.); [email protected] (T.N.); [email protected] (G.W.) * Correspondence: [email protected] Received: 22 November 2020; Accepted: 18 December 2020; Published: 20 December 2020 Abstract: G protein-coupled receptors are linked to various intracellular transducers, each pathway associated with different physiological effects. Biased ligands, capable of activating one pathway over another, are gaining attention for their therapeutic potential, as they could selectively activate beneficial pathways whilst avoiding those responsible for adverse effects. We performed molecular dynamics simulations with known β-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region. Given a loose allosteric coupling of extracellular and intracellular receptor regions, we delineate a concept for biased signaling at serotonin receptors, by which conformational interference with binding pocket closure restricts the signaling repertoire of the receptor. Molecular docking studies of biased ligands gathered from the BiasDB demonstrate that larger ligands only show plausible docking poses in the ergotamine-bound structure, highlighting the conformational constraints associated with bias. This emphasizes the importance of selecting the appropriate receptor conformation on which to base virtual screening workflows in structure-based drug design of biased ligands.
    [Show full text]
  • Wednesday, July 10, 2019 4:00Pm
    Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital
    [Show full text]
  • Ergotamine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Ergotamine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Ergomar Warning Poor blood flow to the hands, feet, or brain has happened when this drug was taken with certain other drugs like clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, nelfinavir, ritonavir, and troleandomycin. This may be very bad or even deadly. Do not take this drug if you are taking any of these drugs. There are many drugs that can do this. Check to make sure that it is safe for you to take this drug with all of your drugs. What is this drug used for? It is used to treat migraine headaches. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Blood vessel disease, heart disease, high blood pressure, kidney disease, liver disease, or a very bad infection. If you have taken almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, Ergotamine 1/6 sumatriptan, or zolmitriptan in the last 24 hours. If you are pregnant or may be pregnant. Do not take this drug if you are pregnant. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Package Leaflet: Information for the Patient Dostinex® 0.5 Mg Tablets
    Package leaflet: Information for the patient Dostinex® 0.5 mg Tablets cabergoline Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dostinex is and what it is used for 2. What you need to know before you take Dostinex 3. How to take Dostinex 4. Possible side effects 5 How to store Dostinex 6. Contents of the pack and other information 1. What Dostinex is and what it is used for - Dostinex contains the active ingredient cabergoline. This medicine belongs to a class of medicines called ‘dopamine agonists’. Dopamine is produced naturally in the body and helps to transmit messages to the brain. - Dostinex is used to stop breast milk production (lactation) soon after childbirth, stillbirth, abortion or miscarriage. It can also be used if you do not want to continue to breast-feed your baby once you have started. - Dostinex can also be used to treat other conditions caused by hormonal disturbance which can result in high levels of prolactin being produced. This includes lack of periods, infrequent and very light menstruation, periods in which ovulation does not occur and secretion of milk from your breast without breast-feeding.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • New Zealand Data Sheet
    New Zealand Data Sheet 1 CAFERGOT (ERGOTAMINE TARTRATE 1 MG AND CAFFEINE 100 MG TABLET) CAFERGOT ergotamine tartrate 1 mg and caffeine 100 mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ergotamine tartrate 1 mg and Caffeine 100 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cafergot tablets are round, flat with bevelled edge, 9 mm diameter, speckled yellow/white, inscribed with a breakline and XL on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of acute attacks of migraine with or without aura in adults. 4.2 Dose and method of administration Cafergot should be given at the first signs of a migraine attack. Dose Adults First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. Children under 18 years Not recommended. Maximum dose per attack or per day Adults: 6 mg ergotamine tartrate = 6 tablets. Maximum weekly dose Adults: 10 mg ergotamine tartrate = 10 tablets. Special populations Renal impairment Cafergot is contraindicated in patients with severe renal impairment (see Contraindications). Hepatic impairment Cafergot is contraindicated in patients with severe hepatic impairment (see Contraindications).
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Ergometrine Maleate
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/237/97-FINAL June 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ERGOMETRINE MALEATE SUMMARY REPORT 1. Ergometrine is a naturally occurring alkaloid found in ergot (Claviceps purpurea). It is classified as a water-soluble lysergic acid derivative, and is an orally-active stimulant of uterine contractions. The maleate salt (ergometrine maleate) exhibits greater stability than the free base and is the usual form in which the alkaloid is used in medicinal products. It is used in veterinary medicine in the control of postpartum uterine haemorrhage, removal of fluid from atonic uteri, to prevent pro-lapsed uteri, and judiciously in terms of timing to aid in suturing the uterus after caesarean section or in replacing an everted uterus. Dose regimens are: cows and mares: 2 to 5 mg/animal (intravenously or intramuscularly); ewes, goats and sows: 0.5 to 1 mg/animal (intramuscularly). In human medicine, it is used orally and parenterally in the prevention and treatment of postpartum haemorrhage caused by uterine atony and for the stimulation of uterine involution. Usual oral doses are 500 µg 3 times daily up to 1.8 mg daily (approximately 0.03 mg/kg bw). Ergot alkaloids have been reported to be present in flour from rye, wheat and barley in amounts ranging from 0.01 to 2.36 mg/kg flour. EU legislation restricts the maximum percentage of ergot tolerated in flour to 0.1%. Total daily human intake of ergot alkaloids from contaminated foodstuffs of plant origin has been estimated as up to 7.8 µg/person.
    [Show full text]
  • The History of Ergot Of
    J R Coll Physicians Edinb 2009; 39:365–9 Paper doi:10.4997/JRCPE.2009.416 © 2009 Royal College of Physicians of Edinburgh The history of ergot of rye (Claviceps purpurea) II: 1900–1940 MR Lee Emeritus Professor of Clinical Pharmacology and Therapeutics, University of Edinburgh, Edinburgh, UK ABSTRACT Ergot, in 1900, was a ‘chemical mess’. Henry Wellcome, the Published online December 2009 pharmaceutical manufacturer, invited Henry Hallett Dale, a physiologist, to join his research department and solve this problem. Dale, in turn, recruited an Correspondence to MR Lee, outstanding group of scientists, including George Barger, Arthur Ewins and 112 Polwarth Terrace, Harold Dudley, who would make distinguished contributions not only to the Edinburgh EH11 1NN chemistry of ergot but also to the identification of acetylcholine, histamine and tel. +44 (0)131 337 7386 tyramine and to studies on their physiological effects. Initially Barger and Dale isolated the compound ergotoxine, but this proved to be a false lead; it was later shown to be a mixture of three different ergot alkaloids. The major success of the Wellcome group was the discovery and isolation of ergometrine, which would prove to be life-saving in postpartum haemorrhage. In 1917 Arthur Stoll and his colleagues started work on ergot at Sandoz Pharmaceuticals in Basel. A series of important results emerged over the next 30 years, including the isolation of ergotamine in 1918, an effective treatment for migraine with aura. KEYWORDS Henry Dale, ergometrine, ergotamine, ergotoxine, migraine, postpartum haemorrhage DECLaratION OF INTERESTS No conflict of interests declared. In 1904, at the age of 29, Henry Hallett Dale joined the Burroughs Wellcome Research Laboratory in London (Figure 1).
    [Show full text]
  • Ergot Alkaloids: a Review on Therapeutic Applications
    European Journal of Medicinal Plants 14(3): 1-17, 2016, Article no.EJMP.25975 ISSN: 2231-0894, NLM ID: 101583475 SCIENCEDOMAIN international www.sciencedomain.org Ergot Alkaloids: A Review on Therapeutic Applications Niti Sharma 1* , Vinay K. Sharma 1, Hemanth Kumar Manikyam 1 1,2 and Acharya Bal Krishna 1Patanjali Natural Coloroma Pvt. Ltd, Haridwar, Uttarakhand - 249404, India. 2University of Patanjali, Haridwar, Uttarakhand - 249402, India. Authors’ contributions This work was carried out in collaboration between all authors. Authors NS and VKS designed the study, wrote the first draft of the manuscript. Authors ABK and HKM supervised the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/EJMP/2016/25975 Editor(s): (1) Marcello Iriti, Professor of Plant Biology and Pathology, Department of Agricultural and Environmental Sciences, Milan State University, Italy. Reviewers: (1) Nyoman Kertia, Gadjah Mada University, Indonesia. (2) Robert Perna, Texas Institute of Rehabilitation Research, Houston, TX, USA. (3) Charu Gupta, AIHRS, Amity University, UP, India. Complete Peer review History: http://sciencedomain.org/review-history/14283 Received 28 th March 2016 Accepted 12 th April 2016 Review Article st Published 21 April 2016 ABSTRACT Ergot of Rye is a plant disease caused by the fungus Claviceps purpurea which infects the grains of cereals and grasses but it is being used for ages for its medicinal properties. All the naturally obtained ergot alkaloids contain tetracyclic ergoline ring system, which makes them structurally similar with other neurotransmitters such as noradrenaline, dopamine or serotonin. Due to this structure homology these alkaloids can be used for the treatment of neuro related conditions like migraine, Parkinson’s disease etc.
    [Show full text]